Randomized Early Versus Late Abciximab in Acute Myocardial Infarction Treated With Primary Coronary Intervention (RELAx-AMI Trial)

Journal of the American College of Cardiology

Volumn 49, Issue 14, 2007, Pages 1517-1524

  Maioli, Mauro ^a   Bellandi, Francesco ^a   Leoncini, Mario ^a   Toso, Anna ^a   Dabizzi, Roberto Piero ^a  

^a MISERICORDIA E DOLCE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; CREATINE KINASE MB;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BOLUS INJECTION; BRAIN HEMORRHAGE; CHRONOLOGY; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART PERFORMANCE; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT; THROMBOCYTOPENIA;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY ANGIOGRAPHY; EMERGENCY TREATMENT; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 34047094799     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2006.12.036     Document Type: Article

References (36)

1. Brener S.J., Barr L.A., Burchenal J.E., et al., ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 98 (1998) 734-741
2. Neumann F.J., Kastrati A., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 35 (2000) 915-921
3. Montalescot G., Barragan P., Wittemberg O., et al., ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344 (2001) 1895-1903
4. Antoniucci D., Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 42 (2003) 1879-1885
5. Montalescot G., Borentain M., Payot L., Collet J.P., and Thomas D. Early vs. late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA 292 (2004) 362-366
6. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. A meta-analysis of randomized trials. JAMA 293 (2005) 1759-1765
7. Godicke J., Flather M., Marko N., et al. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis. Am Heart J 150 (2005) 1015
8. Bellandi F., Maioli M., Leoncini M., Toso A., and Dabizzi R.P. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention. Int J Cardiol 108 (2006) 36-42
9. TIMI Study Group. Definitions used in TIMI trials. Available at: http://www.timi.org. Accessed May 3, 2006.
10. Gibson C.M., Cannon C.P., Daley W.L., et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 93 (1996) 879-888
11. van't Hof A.W., Liem A., Suryapranata H., Hoorntje J.C., de Boer M.J., Zijlstra F., and Zwolle Myocardial Infarction Study Group. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Circulation 97 (1998) 2302-2306
12. Poli A., Fetiveau R., Vandoni P., et al. Integrated analysis of myocardial blush and ST-segment elevation recovery after successful primary angioplasty: real-time grading of microvascular reperfusion and prediction of early and late recovery of left ventricular function. Circulation 106 (2002) 313-318
13. de Lemos J.A., and Braunwald E. ST segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 38 (2001) 1283-1294
14. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography: American Society of Echocardiography Committee on Standards, Subcommittee on Quantification of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
15. Gibbons R.J., Valeti U.S., Araoz P.A., and Jaffe A.S. Quantification of infarct size. J Am Coll Cardiol 44 (2004) 1533-1542
16. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98 (1998) 2695-2701
17. Stone G.W., Grines C.L., Cox A.D., et al., CADILLAC Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 346 (2002) 957-966
18. Stone G.W., Cox D., Garcia E., et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 104 (2001) 636-641
19. Loubeyre C., Morice M.C., Lefevre T., Piechaud P., Louvard Y., and Dumas P. A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. J Am Coll Cardiol 39 (2002) 15-21
20. Goto S., Tamura N., and Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 44 (2004) 316-323
21. Reverter J.C., Beguin S., Kessels H., Kumar R., Hemker H.C., and Culler B.S. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: potential implications for the effect of c7E3 Fab treatment on acute thrombosis and clinical restenosis. J Clin Invest 98 (1996) 863-874
22. Collet J.P., Montalescot G., Lesty C., et al. Effects of abciximab on the architecture of platelet rich clots in patients with acute myocardial infarction undergoing primary coronary angioplasty. Circulation 103 (2001) 2328-2331
23. van den Merkhof L.F., Zijlstra F., Olsson H., et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 33 (1999) 1528-1532
24. Antman E.M., Giugliano R.P., Gibson C.M., et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 trial. Circulation 99 (1999) 2720-2732
25. The SPEED Group. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation 101 (2000) 2788-2794
26. ASSENT-4 Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomized trial. Lancet 367 (2006) 569-578
27. Keeley E.C., Boura J.A., and Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomized trials. Lancet 367 (2006) 579-588
28. Ellis S.G., Armstrong P., Betriu A., et al. Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. Am Heart J 147 (2004) E16
29. Topol E.J. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 97 (1998) 211-218
30. Roe M.T., Ohman E.M., Maas A.C., et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol 37 (2001) 9-18
31. Marzilli M., Sambuceti G., Testa R., and Fedele S. Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. J Am Coll Cardiol 40 (2002) 2102-2109
32. Aymong E.D., Curtis M.J., Youssef M., et al. Abciximab attenuates coronary microvascular endothelial dysfunction after coronary stenting. Circulation 105 (2002) 2981-2985
33. Gawaz M., Neumann F.J., Dickfeld T., et al. Vitronectin receptor (avb3) mediates platelet adhesion to the luminal aspect of endothelial cells: implications for reperfusion in acute myocardial infarction. Circulation 96 (1997) 1809-1818
34. 3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin. Circulation 104 (2001) 582-587
35. Simon D.I., Xu H., Ortlepp S., Rogers C., and Rao N.K. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 17 (1997) 528-535
36. 3 integrin blockade on leukocyte transmigration in vivo. J Immunol 165 (2000) 426-434